Improved RE31 Analogues Containing Modified Nucleic Acid Monomers: Thermodynamic, Structural, and Biological Effects. by Kotkowiak, W et al.
Improved RE31 Analogues Containing Modified Nucleic Acid Monomers: 
Thermodynamic, Structural and Biological Effects 
 Weronika Kotkowiak1,*, Jesper Wengel2, Chris J. Scotton3 and Anna Pasternak1,* 
1Department of Nucleic Acids Bioengineering, Institute of Bioorganic Chemistry, Polish 
Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland 
2Department of Physics, Chemistry and Pharmacy, Biomolecular Nanoscale Engineering 
Center, University of Southern Denmark, Campusvej 55, Odense M, 5230, Denmark 
3Institute of Biomedical and Clinical Science, College of Medicine & Health, University of 
Exeter, St Luke's Campus, Exeter, EX1 2LU, U. K. 
ABSTRACT 
RE31 is a 31-nt DNA aptamer, consisting of the G-quadruplex and a duplex domain, which is 
able to effectively prolong thrombin time. This article reports on the influence of certain 
modified nucleotide residues on thermodynamic and biological properties as well as the folding 
topology of RE31. Particularly, the effect of the presence of canonical nucleosides in unlocked 
nucleic acid (UNA), locked nucleic acid (LNA) or β-L-RNA series was evaluated. The studies 
presented herein show that all modified residues can influence G-quadruplex thermal and 
biological stability in a position dependent manner. The aptamers modified simultaneously with 
UNA at the T15 position and LNAs in the duplex part, possess the highest value of melting 
temperature and a two-fold higher anticoagulant effect. Importantly, RE31 variants modified 
with canonical nucleosides in UNA, LNA or β-L-RNA series exhibit unchanged G-quadruplex 
folding topology. Crucially, introduction of any of the modified residues into RE31 causes 
prolongation of aptamer stability in human serum. 
Keywords: G-quadruplex, thrombin, anticoagulants, DNA, aptamer, unlocked nucleic 
acids  
INTRODUCTION 
The process of blood coagulation is a chain of reactions, during which serum soluble fibrinogen 
is converted into insoluble fibrin and forms clots. The aim of this phenomenon is to create 
a stable haemostatic plug, which will prevent blood from leaking out from blood vessels.1 
A crucial coagulant factor, which plays the main role in converting fibrinogen into fibrin is 
thrombin, a serum multifunctional serine protease.2 In some cases, including coronary surgery, 
cancer therapy, and treatment of cardiovascular diseases to name a few, thrombin action is 
detrimental and needs to be inhibited. Currently, a wide variety of anticoagulant compounds 
have been identified, such as warfarin, low molecular weight heparin and dabigatran, and DNA 
aptamers constitute a unique class among them. 
One the most widely known DNA aptamer is thrombin binding aptamer (TBA), which 
was discovered in 1992 by Louis Bock by in vitro selection.3 The 15-nt DNA oligonucleotide 
folds into an antiparallel, intramolecular G-quadruplex structure with a chair-like conformation. 
The TBA core consists of the G-tetrads linked by one TGT and two TT edge-wise loops (Figure 
1A).4 From the beginning of its discovery, TBA was thought to have interesting anticoagulant 
properties, although it failed in the clinical trials due to substantial therapeutic dose needed to 
achieve therapeutic effect. This, however, did not discourage scientists from seeking to take 
advantage of TBA favorable properties such as cost-effective and efficient chemical synthesis, 
small molecule size and reversibility of action.5 Significant improvements in TBA 
anticoagulant activity have been achieved by introduction of chemical modifications6-11 and 
additional nucleotide residues into its sequence.12  
 Figure 1. Structure of (A) thrombin binding aptamer (TBA), (B) RE31, (C) UNA nucleotide 
monomer, (D) LNA nucleotide monomer and (E) β-L-RNA nucleotide monomer. 
One of the first attempts to create longer oligonucleotide constructs based on the TBA 
sequence were made by Ikebukuro and co-workers.13 They designed a pool of 31-nt 
oligonucleotides consisting of the prototype TBA G-quadruplex structure and five-base-pair 
long duplex regions at the 5′ and 3′ ends connected by three-nucleotide long loops, which 
exhibited higher than TBA inhibitory activity. In 2009, following these previous studies, 
Mazurov and co-workers designed RE31,14 a 31-nt DNA oligomer, which consists of the 
G-quadruplex and a duplex domain linked together by 4 nucleotides (Figure 1B).15 The 
G-quadruplex part is 15-nt fragment, which possesses identical to the TBA sequence and 
structure, while the duplex domain is composed of 6 pairs of complementary nucleotides. RE31 
is able to prolong thrombin time more effectively than TBA does.15 According to  
crystallographic data, it was shown that the duplex part of RE31 gradually transforms into the 
G-quadruplex structure with similarly oriented helical axes of the two fragments.16 Therefore, 
the aptamer is believed to adopt a rod-like shape, which prevents simultaneous binding of both 
RE31 regions to a thrombin molecule. The binding to target protein involves only the 
G-quadruplex region and is assigned to take place in exosite I. Nevertheless, the duplex part, to 
a certain extent, can provide additional contacts with symmetry-related thrombin molecules, 
which result in RE31 increased affinity for its target protein compared with TBA.15, 17  
Unlocked nucleic acid (UNA) is an RNA analog, which contains acyclic sugar moiety.18 
The lack of a bond between the C2′ and C3′ atoms of the ribose ring results in increased 
flexibility of this monomer (Figure 1C) compared with the regular nucleoside, due to the 
enhanced rotational freedom of C-C bonds. It was previously reported that UNAs are able to 
improve the aptamer thermodynamic stability and anticoagulant activity in 
a position-dependent manner.6, 19 On the other hand, introduction of UNAs into RNA or DNA 
helix causes an unfavorable changes of thermodynamic parameters.20, 21 
Locked nucleic acid (LNA), in contrast, is a type of modification of nucleotide residues 
that demonstrate a favorable influence on duplex thermodynamic stability. LNA is an RNA 
analog, which possesses an additional methylene bridge connecting the C2′ and C4′ atoms of 
the ribose ring (Figure 1D).22, 23 Oligonucleotides containing LNA modifications form duplexes 
with increased thermal stabilities and improved selectivity according to the Watson-Crick base 
pairing rules.22 This findings refers to DNA, RNA as well as to DNA-RNA mixed helical 
fragments.23, 24 On the other hand, introduction of LNA into the G-quadruplex can destabilize 
its structure and decrease biological activity.8, 25 
The β-L-RNA derivative is characterized by inversion of the ribose ring stereogenic 
centers configuration (Figure 1E).26 Therefore, introduction of β-L-RNAs into duplex fragments 
results in the occurrence of a left-handed double helical structure. Homochiral L-RNA duplexes 
display unchanged thermodynamic stability in comparison to their naturally occurring 
β-D-RNA counterparts.27 What is more, introduction of β-L-RNAs into double stranded 
oligonucleotides improves their biological stability in human serum and resistance towards 
nucleolytic degradation.26 
Herein, the influence of modified nucleotide residues introduced into RE31 molecule 
was presented for the first time. In more details, the consequences of single and multiple 
substitutions of UNA-A, UNA-C, UNA-G, UNA-U, LNA-A, LNA-G, LNA-T, β-L-RNA-A, 
β-L-RNA-C, β-L-RNA-G and β-L-RNA-U on RE31 folding topology were examined. Moreover, 
the thermal and biological stability of the analyzed aptamers substituted with the modified 
nucleoside residues was  assessed, as well as the anticoagulant properties of the novel RE31 
variants were determined. 
RESULTS AND DISCUSSION 
Thermal denaturation measurements 
Thermal denaturation measurements were employed to verify the influence of single or multiple 
substitution of the nucleoside residues in UNA, LNA and β-L-RNA series on RE31 thermal 
stabilities. This technique allows for recording changes in absorbance of the analyzed probe 
due to temperature increase.28 A valuable parameter, which allows for designation of 
oligonucleotide thermal stability is melting temperature (TM) i.e. the temperature at which 
unfolded and structuralized forms of nucleic acids are in equal proportions. G-quadruplex 
thermodynamic studies were performed at 295 nm wavelength and characterized by the 
presence of hypochromic effect. This phenomenon relies on a decrease in absorbance connected 
with temperature increase and is a result of disappearance of interactions between 
G-tetrads-forming guanosine residues.  
Herein, the attempts to increase the thermal stability of RE31 aptamer via modified 
residues introduction into its G-quadruplex core are presented for the first time. It was 
previously proven that introduction of UNA-U residues into the T3, T7 and T12 positions of TBA 
increases its thermal stability.6 Based on this and taking into consideration the structural 
similarities of the G-quadruplex region of RE31 to the TBA molecule, the positions T11, T15 
and T20 (equivalent to T3, T7 and T12 in TBA) were chosen as positions of substitution of the 
nucleoside residues in the UNA series. Melting analysis revealed that replacement of thymine 
at position T11 and T20 with UNA-U causes a minor increase in thermal stability of RE31 
variants in respect to unmodified aptamer (∆TM for aptamers O1 and O6 was 2.3 and 1.0 °C, 
respectively, Table 1). A similar stabilization was observed for oligomers O2 – O5 possessing 
UNA-A, UNA-C, UNA-G, UNA-U substitution at T15 position. In this case the ∆TM values 
were in the range of 1.8 – 2.8 °C. Considerable improvement in thermal stability was achieved 
via simultaneous substitution of thymidine at T11, T15 and T20 positions by UNA-U residues 
(∆TM for O7 was equal to 5.4 °C). Currently, there are no literature reports concerning the 
influence of modified residues on RE31 chemical and biological properties, however the 
structural similarities of this region to the TBA molecule allow for drawing certain 
comparisons. The above data are consistent with our previous reports indicating beneficial 
influence of introduction of UNA-U at T3, T7 and T12 or other UNAs at T7 on TBA thermal 
stability (these positions are equivalent to T11, T15 and T20 positions in RE31).6, 19 Likewise in 
the TBA case, the favorable effect of UNAs at position T15 is most probably a consequence of 
increased flexibility or the presence of additional 2′ hydroxyl group. Thus, the type of 
heterocyclic base at position T15 seems to be negligible for stabilization of G-quadruplex 
structure. What is more, the lack of involvement in the intramolecular contacts of positions T11, 
T15, and T20 makes them tolerant to chemical modification.16 
The characteristic structure of RE31 gives additional opportunities to increase its 
thermal stability via introduction of modified residues into the duplex fragment. It was 
previously proven that introduction of LNA residues into DNA or RNA duplexes increases their 
thermal stability and improves selectivity in comparison to the corresponding unmodified 
reference.23, 29 What is more, it has been suggested that the most potent utilization of LNAs is 
through alternate spacing with unmodified nucleotides with the first LNA located at the 
penultimate position from the 5ʹ duplex end.30 In the light of the above data, the T2, A4, G6 and 
A8 residues in RE31 compound were replaced by their LNA counterparts (O8), what results in 
a melting temperature increase by 10.8 °C (Table 1). Simultaneous presence of LNAs in duplex 
fragments and one of UNAs at T15 position also caused a significant rise in thermal stability in 
comparison to RE31 variants possessing only UNAs at T15 (the ∆TM values for O9 – O12 were 
in the range 9.2 – 12.6 °C). In contrast, the β-L-RNAs are said to have no influence on duplex 
stability, but exert notably protective effect for helical fragments against nucleolytic 
degradation.27 Therefore, the impact on the aptamer thermal parameters was studied following 
introduction of modified nucleotide residues in β-L-RNA series into RE31 helix and linker 
fragment (T2-A8 and G24-A30). The achieved results stay in accordance with previously 
published data. The increase in G-quadruplex melting temperature was modest and ∆TM for 
O13 was equal to 1.6 °C (Table 1).  
CD spectroscopy 
Circular dichroism (CD) spectroscopy is a useful technique, which provides information about 
nucleic acids conformation and folding topology, based on the different absorbance of 
circularly polarized light.31 The characteristic CD spectrum is a result of different spatial 
orientation of optically active nucleotide residues in certain nucleic acid structures and gives 
information about folding topology of G-quadruplex. Based on experimental data analysis, 
there are distinguished two folding topologies for G-quadruplex: parallel and antiparallel.32, 33 
The G-quadruplex with parallel folding topology has all strands oriented in the same direction 
and is characterized by CD pattern with one positive signal near 260 nm and one negative 
around 240 nm. In contrast, the CD spectra for the antiparallel G-quadruplex folding include 
one maximum near 290 nm and one minimum around 260 nm. It was previously reported that 
the CD spectrum for RE31 displays a shape, which is characteristic for antiparallel folding 
topology with two positive CD bands near 245 and 295 nm and one negative signal around 265 
nm.17, 34 
The CD spectra for oligomers O1-O13 containing  one or more nucleoside residues in 
UNA, LNA and β-L-RNA series were recorded to determine the influence of certain 
modifications on aptamer conformation. All RE31 variants displayed the typical pattern for an 
antiparallel G-quadruplex structure with two maxima near 245 and 295 nm and one minimum 
around 265 nm (Figure 2A and 2B). However, a lack of positive band around 245 nm was 
observed for O13, which could be a consequence of a different chirality or stacking type. The 
CD spectra indicate that modified RE31 variants fold into antiparallel G-quadruplex topology, 
which is comparable to unmodified aptamer at physiological temperature ,  
 
Figure 2. Circular dichroism spectra (A, B) and thermal difference spectra (C, D) of unmodified 
RE31 (black, bold line) and RE31 variants modified with UNA-U at T11 (O1, red line), UNA-A 
at T15 (O2, blue line), UNA-C at T15 (O3, dark cyan line), UNA-G at T15 (O4, magenta line), 
UNA-U at T15 (O5, dark yellow line), UNA-U at T20 (O6, navy blue line), UNA-U at T11, T15, 
T20 (O7, dark red line), LNAs at T2, A4, G6, A8 (O8, pink line), LNAs at T2, A4, G6, A8 and 
UNA-A at T15 (O9, olive line), LNAs at T2, A4, G6, A8 and UNA-C at T15 (O10, dark blue line), 
LNAs at T2, A4, G6, A8 and UNA-G at T15 (O11, orange line), LNAs at T2, A4, G6, A8 and 
UNA-U at T15 (O12, purple line), β-L-RNA at T2-A8 and G24-A30 (O13, violet line). 
Thermal difference spectra 
Thermal difference spectra (TDS) are considered to be complementary to CD spectroscopy, 
which allow to evaluate nucleic acid structures in solution.35 Various structures of nucleic acid 
possess subtle alterations in stacking interactions, which are reflected by characteristic TDS 
patterns.  
 The TDS profiles recorded for oligomers O1-O13 containing single or multiple 
substitution of the nucleoside residues in UNA, LNA and β-L-RNA series were characterized 
by TDS pattern with two positive peaks near 240 and 270 nm and a negative peak around 295 
nm (Figure 2C and 2D). Herein, for the first time the TDS profiles for aptamer RE31 and its 
modified variants are published. Nevertheless, based on similarities to previously published 
data concerning the TDS patterns of unmodified TBA (characterized by presence of two 
maxima around 240 and 270 nm and two minima near 260 and 295 nm), it can be assumed that 
these spectral profiles are characteristic of an antiparallel G-quadruplex structure.6 Thus, 
according to TDS patterns it can be concluded that the presence of modified nucleotides in 
UNA, LNA or β-L-RNA series within RE31 has no influence on the overall folding topology 
of G-quadruplex structure. The results remain in compliance with the circular dichroism and 
thermodynamic studies.  
Thrombin time assay 
Thrombin time assay was employed to verify the influence of nucleotide residues in UNA, LNA 
or β-L-RNA series into RE31 on its inhibitory activity towards human thrombin. The main 
principle of the test is based on thrombin ability to convert plasma-soluble fibrinogen into 
insoluble fibrin, what results in occurrence of blood clots. The parameter that correlates to the 
process is thrombin time defined as the time, after which fibrin clot occurs following the 
addition of exogenous thrombin to blood plasma. Herein, the anticoagulant properties of RE31 
variants were compared by analysis of the anticoagulant effect (AE). The AE parameter is 
defined as differences in the clotting times for (i) plasma with exogenous thrombin and 
oligonucleotides and (ii) plasma with exogenous thrombin only.19 
 It was previously reported that introduction of UNA residues into TBA molecule has 
particularly beneficial influence on its biological activity level.6, 19 Taking into account the 
structural similarities between G-quadruplex region of RE31 and TBA,16 we decided to verify 
whether it is possible to improve the aptamer anticoagulant properties through 
UNA-substitution. The measurements were performed at 0.165 μM concentration of each RE31 
variant. The most favorable effect was achieved via introduction of UNA residues into T15 
position of RE31. The UNA-C substitution at T15 position of RE31 turned out to be particularly 
beneficial (the AE for O3 was 17.08 s, Table 2). The prolongation of thrombin time, in 
comparison to unmodified RE31, was also possible due to introduction of UNA-G at the T15 
position (AE for RE31 and O4 was 11.09 and 12.18 s, respectively). The high tolerance of T15 
position towards substitution with UNA residues can be caused by the lack of involvement of 
the residue at this position in the direct interactions with thrombin or in an energetically 
favorable intramolecular interactions.16 Therefore, the increased flexibility in this loop 
fragment might result in more favorable arrangement of thrombin-RE31 complex. Surprisingly, 
the introduction of UNA-U at T15 position causes some decrease of RE31 anticoagulant activity 
(AE for O5 was 9.66 s). Moreover, the presence of UNA-U within the aptamer loops resulted 
in notable reduction of RE31 anticoagulant potential. The AE parameter measured for aptamers 
modified with UNA-U residues at positions T11 (O1) and T20 (O6) was 6.87 and 4.27 s, 
respectively (). The above effect can be explained by involvement of these two residues in 
formation of hydrogen bonds between RE31 molecule and thrombin.16 Therefore, the increased 
flexibility of the RE31 loops via insertion of UNA residues perturbs favorable intermolecular 
interactions. The simultaneous introduction of UNA-U at positions T11, T15 and T20 provoked 
the most significant reduction of RE31 anticoagulant properties (the AE for O7 was 0.65 s).  
 The introduction of LNA and β-L-RNA residues into aptamer duplex fragment results 
in decreased AE values in comparison to unmodified aptamer (AE for O8 and O13 was 10.09 
and 8.13 s, respectively, Table 2). Surprisingly, this trend could be reversed through additional 
incorporation of UNA residues into T15 position. The most favorable effect was measured for 
aptamer O9 containing both, LNA and UNA-A residues (AE was 23.27 s). An almost equally 
beneficial outcome was found in case of coexistence of canonical LNAs at T2, A4, G6, A8 
positions and UNA-C at T15 position, the AE value for O10 was 21.58 s. Moderate improvement 
in anticoagulant properties was observed for oligomers O11 and O12 containing at the same 
time canonical LNAs at T2, A4, G6, A8 positions and UNA-G or UNA-U at T15 position (the AE 
were 14.10 s and 10.68 s, respectively).  
  Based on data analysis of thrombin time assay conducted for the most favorable RE31 
variants with its various solutions (0.0825, 0.165, 0.330, 0.495, 0.660, 0.825 and 1 µM) it could 
be concluded that the anticoagulant effect strictly depends on aptamers concentration. 
Noteworthy, it is possible to improve the effectiveness of action of particular RE31 variant via 
increase of oligonucleotide concentration. What is more, the results show that aptamers O3 and 
O4 containing single UNA residue at T15 position were characterized by greater AE value than 
their counterpart modified simultaneously with LNAs in duplex fragment and UNAs at T15 
position (oligonucleotides O10 and O11, Figure 3). Aptamers O2 and O9 (modified with single 
UNA-A at T15 or LNAs in duplex fragment and UNA-A at T15, respectively) constituted the 
only exception of this rule (Figure 3). The sudden increase of anticoagulant properties of some 
RE31 variants, especially aptamer O3 (Figure 3), in respect to others could be also observed. 
This phenomenon may be attributable to differences in specificity and competition of 
interactions between the oligonucleotides and thrombin versus remaining plasma proteins. 
Different chemical modifications most probably modulate both kinds of interactions in 
a different way, which results in differences in the dose-response pattern of each 
oligonucleotide. 
 
Figure 3. Concentration dependence of anticoagulant effect of unmodified RE31 (black 
symbol) and RE31 variants modified with UNA-A at T15 (O2, blue symbol), UNA-C at T15 (O3, 
dark cyan symbol), UNA-G at T15 (O4, magenta symbol), LNAs at T2, A4, G6, A8 (O8, pink, 
open symbol), LNAs at T2, A4, G6, A8 and UNA-A at T15 (O9, olive, open symbol), LNAs at 
T2, A4, G6, A8 and UNA-C at T15 (O10, dark blue, open symbol), LNAs at T2, A4, G6, A8 and 
UNA-G at T15 (O11, orange, open symbol). 
 In general, the data analysis shows a favorable influence of simultaneous substitution of 
LNA residues in duplex fragment and UNA-A, UNA-C or UNA-G at T15 position on 
anticoagulant properties of RE31 variants. In addition, aptamers possessing UNA-A, UNA-C 
or UNA-G instead of T15 exhibited greater AE values than unmodified RE31. The observed 
effect is strictly concentration dependent.   
Amidolytic assay 
Thrombin molecule consists of four structural domains: the active site, two anion-binding 
exosites (I and II) and Na+-binding site.36 The active site is directly involved in hydrolysis of 
substrate peptide bond. The two anion-binding exosites are the most positively charged parts of 
thrombin, where binding of its substrates and activity modulator takes place. It was previously 
reported that both TBA and RE31 bind to exosite I.14 Herein, the amidolytic assay was applied 
to assess the influence of modified nucleotides on RE31 aptamer binding to thrombin molecule. 
It is a useful method, which allows to determine the exact localization of interaction based on 
thrombin proteolytic activity. In situation of thrombin catalytic center accessibility, the peptide 
bond of chromogenic substrate H-D-Phe-Pip-Arg-pNA is hydrolyzed and p-nitroaniline is 
generated, what results in appearance of yellow color of probes. Therefore, the thrombin 
catalytic activity can be determined via investigation of the change in the sample absorbance. 
H-D-Phe-Pip-Arg-pNA binds to the thrombin active site even when other functional domains 
are involved in interactions with enzyme substrates or its inhibitors. The calculation of the 
percentage of thrombin activity maintenance (At) was used to determine thrombin ability to 
hydrolyze short peptide H-D-Phe-Pip-Arg-pNA in the presence of tested RE31 variants. The 
At parameter value of 100% corresponds to the absorbance for the thrombin solution measured 
at 405 nm. 
The highest value of thrombin activity was measured for unmodified RE31 and its 
variants containing UNA-C (O3) and UNA-G (O4) at T15 position or simultaneously UNA-G 
at position T15 and canonical LNA residues in duplex part (O11) (Figure 4). The similar effect 
was noted for aptamers modified with UNA-U at position T11 (O1) or simultaneously at T11, 
T15 and T20 positions (O7) or β-L-RNA residues in duplex part (O13, Figure 4). The At 
parameter extended 100% for these RE31 variants. The remaining RE31 variants were 
characterized by a minor decrease in thrombin activity maintenance levels (90% < At <100%). 
The significance level of differences in thrombin activity in the presence of analyzed RE31 
variants was determined via statistical analysis by Student t-test (data not shown). In all cases, 
the p-value was above 0.05, thus the observed differences in At values were not statistically 
significant. Taking together, the data demonstrate that thrombin maintains its ability to 
hydrolyze peptide substrate H-D-Phe-Pip-Arg-pNA in presence of the RE31 variants, and 
therefore it can be concluded that the aptamers inhibitory properties are a results of binding to 
exosite I of thrombin molecule. 
 
Figure 4. The amidolytic activity of thrombin in the presence of unmodified RE31 (black bar) 
and RE31 variants modified with UNA-U at T11 (O1, red bar), UNA-A at T15 (O2, blue bar), 
UNA-C at T15 (O3, dark cyan bar), UNA-G at T15 (O4, magenta bar), UNA-U at T15 (O5, dark 
yellow bar), UNA-U at T20 (O6, navy blue bar), UNA-U at T11, T15, T20 (O7, dark red bar), 
LNAs at T2, A4, G6, A8 (O8, pink bar), LNAs at T2, A4, G6, A8 and UNA-A at T15 (O9, olive 
bar), LNAs at T2, A4, G6, A8 and UNA-C at T15 (O10, dark blue bar), LNAs at T2, A4, G6, A8 
and UNA-G at T15 (O11, orange bar), LNAs at T2, A4, G6, A8 and UNA-U at T15 (O12, purple 
bar), β-L-RNA at T2-A8 and G24-A30 (O13, violet bar). 
 
Surface plasmon resonance 
The determination of the strength of interactions between thrombin and RE31 variants was 
conducted using real-time surface plasmon resonance (SPR) spectroscopy. This optical 
technique allows calculation of the dissociation constant (Kd value) according to the change in 
refractive index. The conventional SPR measurement requires immobilization of one of the 
binding components on the metallic surface of the sensor chip whilst the other is flowed across 
the sensor surface.37 Herein, the group of the most stable and potent RE31 variants were chosen 
for the binding affinity studies.  
The most favorable Kd values, in comparison to unmodified RE31 (for which the Kd 
value was 1.34 nM, Table 2), were obtained for O3 modified with UNA-C residues at position 
T15 (the Kd value was 0.43 nM). Kd values measured for RE31 variants modified with UNA-A, 
UNA-G and UNA-U at T15 position were higher but still more favorable than for unmodified 
RE31 (the Kd values for O2, O4 and O5 were 0.76, 0.68 and 0.75 nM, respectively). The 
introduction of LNA residues into the duplex fragment of RE31 molecule caused a decrease in 
the strength of thrombin-RE31 interactions (the Kd value for O8 was 1.75 nM). Nevertheless, 
the unfavorable influence of LNAs could be alleviated by the presence of UNA-A or UNA-C 
at T15 position (the Kd values for O9 and O10 were 1.15 and 0.90 nM, respectively).  
In general, the Kd values did not directly correspond with the thrombin test results. This 
is most probably due to the complexity of blood coagulation processes and indicates that the 
dissociation constant parameter alone is not sufficient for the assessment of the anticoagulant 
potential. 
Viability in human serum 
Oligonucleotides are rapidly eliminated from the circulation and determination of their 
biostability in human serum is one the most crucial indicators, which allows for prediction of 
their potential in vivo activity. The widely used measure of half-life (T1/2), defined as time in 
which the amount of tested substance decays by half, was employed for determination of 
biostability of RE31 variants in human serum. Various approaches have been proposed to 
extend G-quadruplex serum viability and the chemical modification of the aptamer could help 
solve this issue.19, 38 
Herein, the T1/2 values for RE31 variants were designated via incubation in human serum 
at 37 ºC. The RE31 variants (O8-O13) modified with LNA, β-L-RNA and simultaneously UNA 
and LNA residues were characterized by the most favorable biological stability. In all cases, 
T1/2 was longer than 1440 min in comparison to 364 min for unmodified RE31 (Table 2). The 
T15 substitution by UNA residues also improved the aptamer biostability. Although, in this 
instance the T1/2 for UNA-A (O2) and UNA-C (O3) was equal to 1062 min and for UNA-G 
(O4) and UNA-U (O5) was 1047 and 1018 min, respectively. Only a slightly increased 
biological stability was observed for O6 containing UNA-U at T20 position or O7 possessing 
simultaneously UNA-U at T11, T15 and T20 positions (T1/2 was 524 and 538 min, respectively). 
The achieved results correspond with previously published literature data stating that DNA 
G-quadruplexes modified with nucleotide residues in UNA series  are characterized by 
extended in vitro stability in serum.38 The data presented here further support and extend the 
current state of knowledge in the field. The introduction of LNA residues may provide 
a convenient and effective tool to extend DNA G-quadruplex viability in human serum.  
CONCLUSIONS 
In this paper, examples of RE31 variants possessing artificial nucleotide residues have been 
presented for the first time, along with comprehensive thermodynamic and biological studies 
of RE31 variants modified with nucleotide residues in UNA, LNA and β-L-RNA series.  
 The most favourable influence on RE31 thermal stability had LNAs in the duplex 
fragment or a combination of LNAs in the helix and UNAs at T15 (O8 – O12). Substantial 
improvement was also achieved via ternary substitution of T11, T15 and T20 positions by UNA-U 
(O7). For the rest of the aptamers, only a minor stabilizing effect was observed. The results of 
structural studies confirmed that the overall folding topology of RE31 variants containing 
substitution with modified nucleotide residues at the studied positions was unaffected and that 
all analyzed aptamers form antiparallel G-quadruplex structure at 37 ºC. What is more, it was 
possible to achieve RE31 derivatives characterized by significantly improved anticoagulant 
properties via simultaneous introduction of UNAs at T15 position and LNAs at helix fragment 
(O9 – O11). Slightly smaller but still significant anticoagulant effects were observed for 
aptamers possessing UNAs substitution at T15 position (O2 – O4). It is worth stressing that all 
analyzed RE31 variants possessed extended biological stability. Notably, introduction of LNAs 
and β-L-RNAs into RE31 helical fragment caused meaningful prolongation of aptamers stability 
in human serum (O8 and O13). Additionally, it was proven that entire pool of tested RE31 
variants exerted their inhibitory activity by binding to thrombin exosite I, but their affinity to 
target protein was strictly dependent on the type of modification.  
 The results described herein confirm that both LNA and UNA residues are suitable 
molecular tools to modulate RE31 thermal and biological stability with preservation or 
improvement of its anticoagulant properties. These findings provide new insight in the area of 
application of modified DNA aptamers as promising alternatives to classical antithrombin 
agents. 
EXPERIMENTAL SECTION 
Chemical synthesis of oligonucleotides  
All oligonucleotides were synthesized on an automated RNA/DNA synthesizer using standard 
phosphoramidite chemistry and commercially available nucleoside phosphoramidites.39 The 
deprotection and purification of unmodified oligoribonucleotides or RE31 variants containing 
nucleotide residues in the UNA, LNA and β-L-RNA series were performed as it was described 
previously.20, 40, 41 The purity of oligonucleotides was verified as being above 95% by 20% 
denaturing polyacrylamide gel, and the composition of all oligonucleotides was confirmed by 
MALDI-TOF mass spectrometry.  
UV melting analysis  
Oligonucleotides were dissolved in a buffer containing 100 mM potassium chloride, 20 mM 
sodium cacodylate and 0.5 mM Na2EDTA, pH 7.0. Single-stranded oligonucleotide 
concentrations were calculated based on the absorbance measured above 80 °C and the 
extinction coefficients were calculated, using Oligo Calculator (ribotask.com).42 The samples 
were denatured at 95 °C for 5 min and then cooled to room temperature overnight. The 
measurements were performed for nine different concentrations of G-quadruplex in the 
concentration range of 10-5 – 10-7 M. Absorbance versus temperature curves were obtained 
using the UV melting method at 295 nm in the temperature range of 4 – 90 °C with a heating 
rate of 0.2 °C/min on a JASCO V-650 spectrophotometer equipped with a thermoprogrammer. 
Melting curves were analyzed and the melting points determined by nonlinear curve fitting 
using the MeltWin 3.5 software. Melting temperatures calculated for a 10-4 M concentration of 
oligonucleotide are denoted by TM, and melting points for any other concentration of 
oligonucleotide are denoted by Tm. 
Circular dichroism spectra 
CD spectra were recorded on a JASCO J-815 spectropolarimeter. The oligonucleotides were 
dissolved in a buffer containing 100 mM potassium chloride, 20 mM sodium cacodylate and 
0.5 mM Na2EDTA, pH 7.0, to achieve a sample concentration of 3.0 µM. All samples were 
denatured at 95 °C for 5 min and then slowly cooled to room temperature overnight prior to 
data collection. The spectra were recorded in triplicate at 37 °C in the 205 – 320 nm wavelength 
range. The buffer spectrum was subtracted from the sample spectra. The data analysis was 
performed using the Origin 8.0 software. 
Thermal difference spectra 
The TDS measurements were performed on a JASCO V-650 spectrophotometer equipped with 
a thermoprogrammer. The oligonucleotides were dissolved in a buffer containing 100 mM 
potassium chloride, 20 mM sodium cacodylate and 0.5 mM Na2EDTA, pH 7.0, to achieve 
a sample concentration of 0.1 µM. Absorbance spectra were recorded in triplicate at 4 °C and 
90 °C in the 220 – 335 nm wavelength range. The scan speed was 1000 nm/min with a 1 nm 
data interval. Thermal difference spectra were obtained by subtraction of the low temperature 
absorbance spectra from the high temperature absorbance spectra using the Origin 8.0 software. 
The differential spectra were normalized by dividing the data by its maximum value.35 
Thrombin time assay 
The thrombin time assay was performed using commercially available Dia-TT kit (DIAGON®) 
and coagulometer K-3002 Optic. Each RE31 variant was dissolved in 100 µl Dia-TT reagent, 
to achieve a sample concentration of 0.33 µM. The reaction mixture was incubated at 37 °C for 
5 min and put into sample well of coagulometer K-3002 Optic. Next, 100 µl of citrate plasma 
was added. Each RE31 variant was analyzed using plasma samples derived from five healthy 
volunteers. The sample from each volunteer was measured twice, and the errors of thrombin 
time values obtained from the double measurements did not exceed 6% (Table 2). The 
anticoagulant effect was obtained by subtraction of the time needed for plasma clotting in the 
presence of the aptamers from the time needed for clotting of plasma without aptamer. In 
addition, thrombin time for RE31 variants with the best anticoagulant properties in seven 
different concentrations: 0.0825, 0.165, 0.330, 0.495, 0.660, 0.825, and 1 μM was assigned 
using plasma samples derived from three healthy volunteers. Each experiment was repeated 
twice and the result expressed as mean value. 
Surface plasmon resonance 
The value of dissociation constant (Kd) for chosen RE31 variants was measured using 
a BiacoreTM X100 system (GE Healthcare Life Science), human alpha-thrombin solution 
(Haematologic Technologies, Inc.) and commercially available Biotin CAPture KIT (GE 
Healthcare Life Science). The 5′-biotinylated oligonucleotides were dissolved in a running 
buffer – 10 mM phosphate buffered saline (138 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4, 0.05% Tween-20, pH 7.4) to achieve a sample concentration of 1 µM. The 
samples were denatured at 95 °C for 6 min and then cooled to room temperature overnight. The 
oligonucleotides were immobilized on a chip surface via the streptavidin-biotin coupling 
method. The flow rate was set to 30 µl/min and the unbound oligonucleotide was removed by 
the treatment with 50 mM aqueous NaOH. Next, serially diluted thrombin solution in the 
concentration range of 12.5 - 200 nM along with a bovine serum albumin (BSA, 
Sigma-Aldrich®) and sample with only running buffer were injected. The measurements were 
performed at 25 ºC. After each run, the system was regenerated by treatment with 50 mM 
aqueous NaOH. Data analysis was performed using the Biacore X100 Evaluation software and 
a 1:1 binding mode.  
Amidolytic assay 
Amidolytic assay was used to evaluate the ability of human alpha-thrombin (Haematologic 
Technologies, Inc.) to hydrolyze chromogenic substrate H-D-Phenylalanyl-L-arginine-
p-nitroaniline (H-D-Phe-Pip-Arg-pNA, trade name: S-2238TM, CHROMOGENIX) in the 
presence of chosen RE31 variants. The reaction mixture (150 µl), consisting of the chosen RE31 
variants (1 µM), thrombin (0.4 U/ml) and reaction buffer (0.1 M Tris pH 8.2, 150 mM NaCl, 
5 mM KCl, 0.1% BSA), was incubated at 37 ºC for 5 min. Next, 50 µl of 2 mM chromogenic 
substrate H-D-Phe-Pip-Arg-pNA was added. The amount of released p-nitroaniline was 
measured at 405 nm using a microplate reader xMarkTM (Bio-Rad). Data analysis was 
performed using Microsoft Excel 2013 software. Each experiment was repeated in triplicate 
and the result expressed as mean value. 
Viability of oligonucleotides in human serum 
The amount of 110 pmol of 5ʹ-FAM labeled oligonucleotides was dissolved in 20 μl of 1 x PBS 
buffer containing 100 mM potassium chloride. The samples were denatured at 90 °C for 6 min 
and then cooled to room temperature overnight. Afterwards, 200 µl of human serum from 
human male AB plasma (Sigma-Aldrich) was added, and the samples were incubated at 37 °C. 
Aliquots of 5 µl were removed after 0, 10, 20, 40, 60, 120, 180 and 1440 min (for less stable 
aptamers) or after 0, 20, 40, 60, 120, 240, 480, 1440, 1680, 1920 and 2880 min (for more stable 
aptamers) of incubation and were then mixed with 5 µl of a 70% deionized formamide solution 
containing 50 mM EDTA and cooled on dry ice to quench the reaction. The samples were 
loaded on a 12% denaturing polyacrylamide gel prepared in 1 x TBE buffer. Polyacrylamide 
gel electrophoresis (PAGE) in denaturing condition was performed in 1 x TBE buffer at 20 W 
for 3 h at room temperature. The resultant gel was imaged and quantified using a Fuji 
Phosphorimager and MultiGauge Analysis Software. 
AUTHOR INFORMATION 
Corresponding Author 
*To whom correspondence should be addressed. Tel: + 48 618 528 503; Fax: +48 618 520 532; 
E-mail: apa@ibch.poznan.pl (to A.P.); kawecka@ibch.poznan.pl (to W.K.) .
Author Contributions 
W.K. performed all experiments and wrote the paper. J.W. supervised the SPR measurements. 
C.J.S. proofed the paper. A.P. performed oligonucleotide synthesis, supervised all the 
experiments and proofed the paper. All authors have given approval to the final version of the 
manuscript.  
ACKNOWLEDGMENTS 
This work has been supported by the National Science Center  
[UMO-2015/19/N/NZ5/02246 to W.K., UMO-2013/10/E/NZ1/00741 and 
UMO-2017/25/B/NZ7/00127 to A.P.] and by the Polish Ministry of Science and Higher 
Education [27/SN/2018 to W.K.]. We also thank the WILLUM Foundation for funding the 
Biomolecular Nanoscale Engineering Center (BioNEC; grant number 00007206).  
ABBREVIATIONS USED 
AE, anticoagulant effect; At, percentage of thrombin activity maintenance; Kd, dissociation 
constant; LNA, locked nucleic acid; SPR, surface plasmon resonance; TBA, thrombin binding 
aptamer; TDS, thermal difference spectra; TM, melting temperature; T1/2, half-life; UNA, 
unlocked nucleic acid 
REFERENCES 
1. Walker, C. P.; Royston, D. Thrombin generation and its inhibition: a review of the scientific 
basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002, 88, 848-863. 
2. Coppens, M.; Eikelboom, J. W.; Gustafsson, D.; Weitz, J. I.; Hirsh, J. Translational success 
stories: development of direct thrombin inhibitors. Circ Res 2012, 111, 920-929. 
3. Bock, L. C.; Griffin, L. C.; Latham, J. A.; Vermaas, E. H.; Toole, J. J. Selection of single-
stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355, 564-566. 
4. Pica, A.; Russo Krauss, I.; Merlino, A.; Nagatoishi, S.; Sugimoto, N.; Sica, F. Dissecting the 
contribution of thrombin exosite I in the recognition of thrombin binding aptamer. FEBS J 2013, 280, 
6581-6588. 
5. Avino, A.; Fabrega, C.; Tintore, M.; Eritja, R. Thrombin binding aptamer, more than a simple 
aptamer: chemically modified derivatives and biomedical applications. Curr Pharm Des 2012, 18, 2036-
2047. 
6. Pasternak, A.; Hernandez, F. J.; Rasmussen, L. M.; Vester, B.; Wengel, J. Improved thrombin 
binding aptamer by incorporation of a single unlocked nucleic acid monomer. Nucleic Acids Res 2011, 
39, 1155-1164. 
7. Mendelboum Raviv, S.; Horvath, A.; Aradi, J.; Bagoly, Z.; Fazakas, F.; Batta, Z.; Muszbek, L.; 
Harsfalvi, J. 4-thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot 
formation, platelet aggregation and thrombus growth on subendothelial matrix. J Thromb Haemost 
2008, 6, 1764-1771. 
8. Bonifacio, L.; Church, F. C.; Jarstfer, M. B. Effect of locked-nucleic acid on a biologically 
active g-quadruplex. A structure-activity relationship of the thrombin aptamer. Int J Mol Sci 2008, 9, 
422-433. 
9. Jensen, T. B.; Henriksen, J. R.; Rasmussen, B. E.; Rasmussen, L. M.; Andresen, T. L.; Wengel, 
J.; Pasternak, A. Thermodynamic and biological evaluation of a thrombin binding aptamer modified 
with several unlocked nucleic acid (UNA) monomers and a 2'-C-piperazino-UNA monomer. Bioorg 
Med Chem 2011, 19, 4739-4745. 
10. Nallagatla, S. R.; Heuberger, B.; Haque, A.; Switzer, C. Combinatorial synthesis of thrombin-
binding aptamers containing iso-guanine. J Comb Chem 2009, 11, 364-369. 
11. Borbone, N.; Bucci, M.; Oliviero, G.; Morelli, E.; Amato, J.; D'Atri, V.; D'Errico, S.; Vellecco, 
V.; Cirino, G.; Piccialli, G.; Fattorusso, C.; Varra, M.; Mayol, L.; Persico, M.; Scuotto, M. Investigating 
the role of T7 and T12 residues on the biological properties of thrombin-binding aptamer: enhancement 
of anticoagulant activity by a single nucleobase modification. J Med Chem 2012, 55, 10716-10728. 
12. Macaya, R. F.; Waldron, J. A.; Beutel, B. A.; Gao, H.; Joesten, M. E.; Yang, M.; Patel, R.; 
Bertelsen, A. H.; Cook, A. F. Structural and functional characterization of potent antithrombotic 
oligonucleotides possessing both quadruplex and duplex motifs. Biochemistry 1995, 34, 4478-4492. 
13. Ikebukuro, K.; Okumura, Y.; Sumikura, K.; Karube, I. A novel method of screening thrombin-
inhibiting DNA aptamers using an evolution-mimicking algorithm. Nucleic Acids Res 2005, 33, e108-
e108. 
14. Mazurov, A. V.; Titaeva, E. V.; Khaspekova, S. G.; Storojilova, A. N.; Spiridonova, V. A.; 
Kopylov, A. M.; Dobrovolsky, A. B. Characteristics of a new DNA aptamer, direct inhibitor of 
thrombin. Bull Exp Biol Med 2011, 150, 422-425. 
15. Spiridonova V. A., Glinkina K. A., Gainutdinov A. A. Arutyunyan A. M. Production of 
thrombin complexes with DNA aptamers containing G-quadruplex and different duplexes. JNephrol 
Ther 2014, 4, 3-6. 
16. Russo Krauss, I.; Spiridonova, V.; Pica, A.; Napolitano, V.; Sica, F. Different 
duplex/quadruplex junctions determine the properties of anti-thrombin aptamers with mixed folding. 
Nucleic Acids Res 2016, 44, 983-991. 
17. Spiridonova, V. A.; Barinova, K. V.; Glinkina, K. A.; Melnichuk, A. V.; Gainutdynov, A. A.; 
Safenkova, I. V.; Dzantiev, B. B. A family of DNA aptamers with varied duplex region length that forms 
complexes with thrombin and prothrombin. FEBS Lett 2015, 589, 2043-2049. 
18. Nielsen, P.; Dreioe, L. H.; Wengel, J. Synthesis and evaluation of oligodeoxynucleotides 
containing acyclic nucleosides: introduction of three novel analogues and a summary. Bioorg Med Chem 
1995, 3, 19-28. 
19. Kotkowiak, W.; Lisowiec-Wachnicka, J.; Grynda, J.; Kierzek, R.; Wengel, J.; Pasternak, A. 
Thermodynamic, anticoagulant, and antiproliferative properties of thrombin binding aptamer containing 
novel UNA derivative. Mol Ther Nucleic Acids 2018, 10, 304-316. 
20. Langkjaer, N.; Pasternak, A.; Wengel, J. UNA (unlocked nucleic acid): a flexible RNA mimic 
that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 2009, 17, 5420-5425. 
21. Pasternak, A.; Wengel, J. Thermodynamics of RNA duplexes modified with unlocked nucleic 
acid nucleotides. Nucleic Acids Res 2010, 38, 6697-6706. 
22. Singh, S. K.; Koshkin, A. A.; Wengel, J.; Nielsen, P. LNA (locked nucleic acids): synthesis and 
high-affinity nucleic acid recognition. Chem Comm 1998, 455-456. 
23. Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, 
C. E.; Wengel, J. LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-
methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented 
nucleic acid recognition. Tetrahedron 1998, 54, 3607-3630. 
24. Kumar, R.; Singh, S. K.; Koshkin, A. A.; Rajwanshi, V. K.; Meldgaard, M.; Wengel, J. The first 
analogues of LNA (Locked Nucleic Acids): phosphorothioate-LNA and 2′-thio-LNA. Bioorg Med 
Chem Lett 1998, 8, 2219-2222. 
25. Virno, A.; Randazzo, A.; Giancola, C.; Bucci, M.; Cirino, G.; Mayol, L. A novel thrombin 
binding aptamer containing a G-LNA residue. Bioorg Med Chem 2007, 15, 5710-5718. 
26. D'Alonzo, D.; Guaragna, A.; Palumbo, G. Exploring the role of chirality in nucleic acid 
recognition. Chem Biodivers 2011, 8, 373-413. 
27. Szabat, M.; Gudanis, D.; Kotkowiak, W.; Gdaniec, Z.; Kierzek, R.; Pasternak, A. 
Thermodynamic features of structural motifs formed by beta-L-RNA. PLoS One 2016, 11, e0149478. 
28. Mergny, J. L.; Lacroix, L. Analysis of thermal melting curves. Oligonucleotides 2003, 13, 515-
537. 
29. Campbell, M. A.; Wengel, J. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting 
structures work towards common therapeutic goals. Chem Soc Rev 2011, 40, 5680-5689. 
30. Kierzek, E.; Ciesielska, A.; Pasternak, K.; Mathews, D. H.; Turner, D. H.; Kierzek, R. The 
influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA 
heteroduplexes. Nucleic Acids Res 2005, 33, 5082-5093. 
31. Martin, S. R.; Schilstra, M. J. Circular dichroism and its application to the study of biomolecules. 
Methods Cell Biol 2008, 84, 263-293. 
32. Burge, S.; Parkinson, G. N.; Hazel, P.; Todd, A. K.; Neidle, S. Quadruplex DNA: sequence, 
topology and structure. Nucleic Acids Res 2006, 34, 5402-5415. 
33. Del Villar-Guerra, R.; Trent, J. O.; Chaires, J. B. G-quadruplex secondary structure obtained 
from circular dichroism spectroscopy. Angew Chem Int Ed Engl 2018, 57, 7171-7175. 
34. Spiridonova, V. A.; Novikova, T. M.; Nikulina, D. M.; Shishkina, T. A.; Golubkina, E. V.; 
Dyukareva, O. S.; Trizno, N. N. Complex formation with protamine prolongs the thrombin-inhibiting 
effect of DNA aptamer in vivo. Biochimie 2018, 145, 158-162. 
35. Mergny, J. L.; Li, J.; Lacroix, L.; Amrane, S.; Chaires, J. B. Thermal difference spectra: a 
specific signature for nucleic acid structures. Nucleic Acids Res 2005, 33, e138. 
36. Crawley, J. T.; Zanardelli, S.; Chion, C. K.; Lane, D. A. The central role of thrombin in 
hemostasis. J Thromb Haemost 2007, 5 Suppl 1, 95-101. 
37. Patching, S. G. Surface plasmon resonance spectroscopy for characterisation of membrane 
protein–ligand interactions and its potential for drug discovery. Biochim Biophys Acta 2014, 1838, 43-
55. 
38. Agarwal, T.; Kumar, S.; Maiti, S. Unlocking G-quadruplex: effect of unlocked nucleic acid on 
G-quadruplex stability. Biochimie 2011, 93, 1694-1700. 
39. Roy, S.; Caruthers, M. Synthesis of DNA/RNA and their analogs via phosphoramidite and H-
phosphonate chemistries. Molecules 2013, 18, 14268-14284. 
40. Kotkowiak, W.; Kotkowiak, M.; Kierzek, R.; Pasternak, A. Unlocked nucleic acids: 
implications of increased conformational flexibility for RNA/DNA triplex formation. Biochem J 2014, 
464, 203-211. 
41. Lopez-Gomollon, S.; Nicolas, F. E. Purification of DNA Oligos by Denaturing Polyacrylamide 
Gel Electrophoresis (PAGE). In Methods Enzymol; Lorsch, J., Ed.; Elsevier,2013, 529, 65-83. 
42. Mergny, J. L.; Lacroix, L. UV Melting of G-Quadruplexes. In Curr Protoc Nucleic Acid Chem 
2009, 37, 17.1.1-17.1.15. 
  
Table 1. Melting temperatures of RE31 variants modified with UNA-A (AU), UNA-C (CU), UNA-G (GU), UNA-U (UU), LNA-A (AL), 
LNA-G (GL), LNA-T (TL), β-L-RNA-A (Aβ), β-L-RNA-C (Cβ), β-L-RNA-G (Gβ) and β-L-RNA-U (Uβ).a,b 
Name 
Position of 
modification 
Sequence 
(5ʹ-3ʹ) 
Melting curve fits 
TM
 
(˚C) 
 
TM  
(˚C) 
RE31  GTGACGTAGGTTGGTGTGGTTGGGGCGTCACc 51.6 ± 0.4  0 
O1 T11 GTGACGTAGGUUTGGTGTGGTTGGGGCGTCAC 53.9 ± 0.4  2.3 
O2 T15 GTGACGTAGGTTGGAUGTGGTTGGGGCGTCAC 53.4 ± 0.2  1.8 
O3 T15 GTGACGTAGGTTGGCUGTGGTTGGGGCGTCAC 54.0 ± 0.1  2.4 
O4 T15 GTGACGTAGGTTGGGUGTGGTTGGGGCGTCAC 54.2 ± 0.3  2.6 
O5 T15 GTGACGTAGGTTGGUUGTGGTTGGGGCGTCAC 54.4 ± 0.2  2.8 
O6 T20 GTGACGTAGGTTGGTGTGGUUTGGGGCGTCAC 52.6 ± 0.5  1.0 
O7 T11, T15, T20 GTGACGTAGGUUTGGUUGTGGUUTGGGGCGTCAC 57.0 ± 0.1  5.4 
O8 T2, A4, G6, A8 GTLGALCGLTALGGTTGGTGTGGTTGGGGCGTCACc 62.4 ± 0.4  10.8 
O9 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGAUGTGGTTGGGGCGTCACc 61.9 ± 0.9  10.3 
O10 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGCUGTGGTTGGGGCGTCACc 63.1 ± 0.6  11.5 
O11 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGGUGTGGTTGGGGCGTCACc 64.2 ± 0.4  12.6 
O12 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGUUGTGGTTGGGGCGTCACc 60.8 ± 0.5  9.2 
O13 T2-A8, G24-A30 GUβGβAβCβGβUβAβGGTTGGTGTGGTTGGGβGβCβGβUβCβAβC 53.2 ± 0.2  1.6 
a buffer: 100 mM KCl, 20 mM sodium cacodylate, 0.5 mM EDTA(Na)2, pH 7.0. 
b The measurements were performed at 295 nm.  
c The measurements of selected RE31 variants were also performed in 1 x PBS buffer, pH 7.4. The data are in Table S1 (Supporting  
Information). 
 
 
 
  
Table 2. The anticoagulant properties (TT, AE) a, dissociation constant (Kd) and biostability (T1/2) of RE31 variants modified with UNA-A (AU), UNA-C (CU), UNA-G 
(GU), UNA-U (UU), LNA-A (AL), LNA-G (GL), LNA-T (TL), β-L-RNA-A (Aβ), β-L-RNA-C (Cβ), β-L-RNA-G (Gβ) and β-L-RNA-U (Uβ). 
Name 
Position of 
modification 
Sequence 
(5ʹ-3ʹ) 
TTa,b 
[s] 
AE 
[s] 
Kd 
[nM] 
 
T1/2 
[min] 
RE31  GTGACGTAGGTTGGTGTGGTTGGGGCGTCAC 30.07 ± 0.40 11.09 ± 0.48 1.34 ± 0.05 364 
O1 T11 GTGACGTAGGU
UTGGTGTGGTTGGGGCGTCAC 25.50 ± 0.67 6.87 ± 0.39 n.d. 378 
O2 T15 GTGACGTAGGTTGGAUGTGGTTGGGGCGTCAC 30.53 ± 1.23 11.55 ± 1.13 0.76 ± 0.02 1062 
O3 T15 GTGACGTAGGTTGGCUGTGGTTGGGGCGTCAC 35.88 ± 1.71 17.08 ± 2.31 0.43 ± 0.01 1062 
O4 T15 GTGACGTAGGTTGGGUGTGGTTGGGGCGTCAC 30.98 ± 1.98 12.18 ± 1.64 0.68 ± 0.05 1047 
O5 T15 GTGACGTAGGTTGGU
UGTGGTTGGGGCGTCAC 27.83 ± 0.28 9.66 ± 0.48 0.75 ± 0.05 1018 
O6 T20 GTGACGTAGGTTGGTGTGGU
UTGGGGCGTCAC 22.90 ± 0.73 4.27 ± 0.46 n.d. 524 
O7 T11, T15, T20 GTGACGTAGGU
UTGGUUGTGGUUTGGGGCGTCAC 20.80 ± 0.80 0.65 ± 0.30 n.d. 538 
O8 T2, A4, G6, A8 GTLGALCGLTALGGTTGGTGTGGTTGGGGCGTCAC 29.10 ± 0.37 10.09 ± 0.75 1.75 ± 0.12 > 1440 
O9 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGAUGTGGTTGGGGCGTCAC 42.12 ± 2.51 23.27 ± 3.06 1.15 ± 0.02 > 1440 
O10 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGCUGTGGTTGGGGCGTCAC 41.17 ± 1.18 21.58 ± 0.33 0.90 ± 0.03 >1440 
O11 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGGUGTGGTTGGGGCGTCAC 33.05 ± 1.18 14.10 ± 0.98 n.d. > 1440 
O12 T2, A4, G6, A8, T15 GTLGALCGLTALGGTTGGUUGTGGTTGGGGCGTCAC 29.58 ± 1.29 10.68 ± 0.18 n.d. > 1440 
O13 T2-A8, G24-A30 GUβGβAβCβGβUβAβGGTTGGTGTGGTTGGGβGβCβGβUβCβAβC 26.77 ± 0.42 8.13 ± 0.81 n.d. > 1440 
a Thrombin time value for plasma without aptamers was in the range of 17.4 – 21.6 s. 
b The measurements were performed for 0.165 μM aptamer concentration. 
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